Leap Therapeutics Announces Encouraging Data from TRX518 Phase 1 in Immunosuppressive Cell Reduction (MCUR)
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist
November 12, 2016 2:00 PM ESTData Presented During the Presidential Session at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Leap Therapeutics, Inc. today announced the presentation of data from its Phase 1 clinical trial of TRX518 in patients with advanced relapsed or refractory solid tumors. Roberta Zappasodi, Ph.D., Parker Institute Scholar and Research Scholar in the Ludwig Collaborative Laboratory at Memorial Sloan Kettering Cancer Center, a site participating in the Phase 1 study, led an oral presentation during the Presidential Session entitled Analysis of pharmacodynamic biomarkers in the first-in-human... More